Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Emulating start-up success with purpose-built data tools

Posted on December 12th, 2018 by

Pharma R&D

Arctic Pharma NEW

Innovation used to be almost solely accredited to Big Pharma, but many of the more established businesses in the industry are finding that their rate of discovery is slowing as they try to find answers to some the industry’s biggest problems, such as antibiotic resistance. Continue reading “Emulating start-up success with purpose-built data tools” »

Games and Events: A New Era of Coopetition in Pharma R&D

Posted on December 8th, 2018 by

Pharma R&D

Coopetition new

Although R&D competition remains as fierce as ever, many pharmaceutical companies engage in various types of cooperation and partnership ventures to help drive innovation. The goal of coopetition — when companies cooperate on certain projects while maintaining a competitive stance — is to make drug development more efficient and effective. Continue reading “Games and Events: A New Era of Coopetition in Pharma R&D” »

Researchers at LegoChem Biosciences Share How Information Solutions Power Their Innovative Work

Posted on December 4th, 2018 by

Pharma R&D

LCB new

With its groundbreaking work in developing antibody-drug conjugates, antibiotics, anti-coagulants and anti-cancer therapies, LegoChem Biosciences was already doing important research before joining The Hive. Continue reading “Researchers at LegoChem Biosciences Share How Information Solutions Power Their Innovative Work” »

Small Biotechs Progressing Beyond Startup Status

Posted on November 29th, 2018 by

Pharma R&D

Anja

When is a startup no longer a startup? Small biotech companies armed with a talented crop of scientists have been springing up all across the pharma landscape for the last several years, establishing buzzing hubs of innovation. Not all of them find their research efforts successful, but many do and then go on to be acquired by larger pharmaceutical firms that have the resources to bring their ideas to fruition. Continue reading “Small Biotechs Progressing Beyond Startup Status” »

Tackling Unmet Needs with a Proprietary Platform

Posted on November 22nd, 2018 by

Pharma R&D

legochem new

Since our founding back in 2006, LegoChem Biosciences (LCB) has focused on the research and development of anti-biotic, anti-coagulant, anti-fibrosis and Antibody-Drug Conjugate (ADC) therapeutics based on our proprietary platform technology, LegoChemistry™ & Conjuall™. LCB is comprised of researchers who have varied backgrounds and R&D experiences, including the development of Factive, the first US FDA-approved drug developed in Korea. Continue reading “Tackling Unmet Needs with a Proprietary Platform” »

Finding Answers Where You Least Expect Them

Posted on November 19th, 2018 by

Pharma R&D

drug discovery new

The hard work of drug development often goes down well-worn paths that can be tedious, time-consuming and frustrating, but – with time and dedication – can yield exciting results. Sometimes, however, scientists who think outside the box find themselves taking unconventional routes in their efforts to create innovative new therapies. Continue reading “Finding Answers Where You Least Expect Them” »

  1. 1
  2. 2
  3. 3
  4. …
  5. 60


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.